Patents by Inventor Tony Tianyi Wang

Tony Tianyi Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE CELL CLONES HARBORING REPLICATING SARS-COV-2 RNA
    Publication number: 20250250647
    Abstract: Coronavirus genomes comprising non-native SARS-CoV-2 RNAs having genetically inactivated spike (S), envelope (E), and membrane (M) genes, and optionally a genetically inactivated nucleocapsid (NP) gene, are provided. Such coronavirus genomes further include a reporter gene and a marker gene, and substitutions within a non-structural protein 1 (Nsp1) gene (such as K164A and H165A). Also provided are cells containing the coronavirus genomes, for example, stable cell clones having the isolated non-native coronavirus genome autonomously replicating inside the cells. Also provided are methods of using such cells, for example, methods of identifying anti-viral compounds, such as quantitative high-throughput screening methods that can optionally be performed in a biosafety level 2 (BSL2) laboratory.
    Type: Application
    Filed: October 31, 2022
    Publication date: August 7, 2025
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human
    Inventors: Tony Tianyi Wang, Shufeng Liu
  • Compositions and methods for inhibiting viral infection
    Patent number: 11427595
    Abstract: Described herein are compounds, agents, compositions, and methods related to the treatment of a viral infection (e.g., Hepatitis C viral infection). In particular, the compounds, agents, compositions, and methods described herein inhibit viral entry into a target cell.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: August 30, 2022
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, SRI INTERNATIONAL
    Inventors: John A. Porco, Jr., Wenhan Zhang, Tony Tianyi Wang, Shufeng Liu
  • COMPOSITIONS AND METHODS FOR INHIBITING VIRAL INFECTION
    Publication number: 20200123170
    Abstract: Described herein are compounds, agents, compositions, and methods related to the treatment of a viral infection (e.g., Hepatitis C viral infection). In particular, the compounds, agents, compositions, and methods described herein inhibit viral entry into a target cell.
    Type: Application
    Filed: October 22, 2019
    Publication date: April 23, 2020
    Applicants: Trustees of Boston University, SRI International
    Inventors: John A. Porco, Jr., Wenhan Zhang, Tony Tianyi Wang, Shufeng Liu
  • Apolipoprotein E polypeptides and their use
    Patent number: 10125184
    Abstract: Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication. Nucleic acids encoding these polypeptides are also disclosed, as well as methods.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: November 13, 2018
    Assignees: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, UNIVERSITY OF SOUTH CAROLINA
    Inventors: Tony Tianyi Wang, Shufeng Liu, Fan Daping
  • Aglaroxin C and derivatives as HCV entry inhibitors
    Patent number: 10085988
    Abstract: A rocaglamide or a rocaglate derivative, particularly aglaroxin C, blocks hepatitis C virus (HCV) entry with improved potency and therapeutic index.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: October 2, 2018
    Assignees: SRI International, Trustees of Boston University
    Inventors: Tony Tianyi Wang, Shufeng Liu, Wenyu Wang, Neil Lajkiewicz, John A. Porco, Jr.